Clinical Trial to Study Medical Cannabis Efficacy on Long Covid Gets Green Light

Cannabis Long Covid - GCI Content Hub - Global Cannabis Intelligence

The clinical trial will assess the effectiveness of cannabis based medicines on the symptoms of long Covid in UK sufferers.

According to Business News Australia, medicinal cannabis company Bod has received authorisation to conduct a clinical trial evaluating the efficacy of its products on long Covid sufferers in the UK.

This clinical trial announcement follows the recent publication of research showing how cannabis compounds prevent infection by Covid-19.

What is long Covid?

Following infection by the virus, some people have experienced long-term symptoms which can last for weeks or months after the initial infection has gone.

The UK’s Office of National Statistics estimates that 1.3 million people in the United Kingdom are suffering from the extended effects of long Covid. Moreover, roughly 1 in 40 people experience Covid-19 symptoms lasting at least three months.

The chances of suffering from long-term symptoms does not seem to be linked to how ill someone is when they first get Covid-19.

Symptoms of long Covid include: extreme tiredness, shortness of breath, chest pain, loss of concentration, chronic pain, tinnitus, insomnia, dizziness, depression and anxiety.

Medical cannabis for long Covid?

Bod Australia have announced receipt of Clinical Trial Authorisation from the UK’s Medicines and Healthcare Products Regulatory Agency earlier this week. The research will assess the effectiveness of the company’s MediCabilis 5% CBD product, in treating the effects of long Covid.

Authorisation follows the completion of a final protocol design and ethics approval, meaning Bod can commence participant recruitment immediately.

The study plans to recruit 30 trial participants who have been suffering from the effects of long Covid for more than 8 weeks following an initial Covid-19 infection.

Participants will be administered daily doses of Bod’s 5% CBD product over a six-month period, during which efficacy data will be collected. Researchers hope that this data will provide a pathway towards commercialisation of a potential treatment product to be made available to long Covid sufferers.

To explore additional cannabis content, click here.